At the European Society of Cardiology, Coventry Hospital in the UK presented data on the use of VIVO in very complex ventricular tachycardia patients. This center has now enrolled over forty patients ...
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...
Such techniques can be automatically applied using implantable cardioverter defibrillators (ICDs) and offer the potential for painless termination of ventricular tachycardia (VT). Reduction in ...